candesartan has been researched along with Bright Disease in 7 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1." | 5.12 | A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. ( Kanno, Y; Shoda, J; Suzuki, H, 2006) |
| "Candesartan promotes a complementary antiproteinuric and a small antihypertensive effect after a treatment period of 8 weeks in patients with chronic glomerulonephritis when given in conjunction with an ACEI." | 5.10 | Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. ( Bader, BD; Berger, ED; Ebert, C; Erley, CM; Risler, T, 2002) |
| "The antifibrotic substance pirfenidone and the angiotensin II type I receptor antagonist candesartan cilexetil, given alone and in combination, were tested in rats with chronic anti-glomerular basement membrane glomerulonephritis (anti-GBM GN)." | 3.73 | Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. ( Forslund, T; Iversen, BM; Leh, S; Margolin, SB; Vaagnes, Ø, 2005) |
| "5-year prospective study compared the effects of angiotensin II receptor blocker, candesartan(n = 21), and ACE inhibitor(ACEI, n = 23) on proteinuria and renal function in patients with moderate renal impairment due to chronic glomerulonephritis." | 3.71 | [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis]. ( Iigaya, K; Imai, M; Kumagai, H; Matsuura, T; Onami, T; Sakata, K; Saruta, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumagai, H | 1 |
| Sakata, K | 1 |
| Matsuura, T | 1 |
| Imai, M | 1 |
| Onami, T | 1 |
| Iigaya, K | 1 |
| Saruta, T | 1 |
| Hollenberg, NK | 1 |
| Leh, S | 1 |
| Vaagnes, Ø | 1 |
| Margolin, SB | 1 |
| Iversen, BM | 1 |
| Forslund, T | 1 |
| Chang, A | 1 |
| Logar, CM | 1 |
| Finn, LS | 1 |
| Alpers, CE | 1 |
| Seliger, SL | 1 |
| Shoda, J | 1 |
| Kanno, Y | 1 |
| Suzuki, H | 1 |
| Kurokawa, K | 1 |
| Berger, ED | 1 |
| Bader, BD | 1 |
| Ebert, C | 1 |
| Risler, T | 1 |
| Erley, CM | 1 |
3 trials available for candesartan and Bright Disease
| Article | Year |
|---|---|
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Ben | 2006 |
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
4 other studies available for candesartan and Bright Disease
| Article | Year |
|---|---|
[Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2002 |
Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.
Topics: Analysis of Variance; Animals; Antibodies; Autoantibodies; Base Sequence; Benzimidazoles; Biopsy, Ne | 2005 |
A rare cause of necrotizing and crescentic glomerulonephritis in a young adult male.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autoa | 2005 |
Effects of candesartan on the proteinuria of chronic glomerulonephritis.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arterioles; Benzimidazoles; | 1999 |